Serum Globotriaosylceramide Assay as a Screening Test for Fabry Disease in Patients with ESRD on Maintenance Dialysis in Korea
Jeong-Yup Kim, Young-Youl Hyun, Ji-Eun Lee, Hye-Ran Yoon, Gu-Hwan Kim, Han-Wook Yoo, Seong-Tae Cho, No-Won Chun, Byoung-Chunn Jeoung, Hwa-Jung Kim, Keong-Wook Kim, Seong-Nam Kim, Yung-A Kim, Hyun-Ah Lee, Jong-Young Lee, Yung-Chun Lee, Hun-Kwan Lim, Keong-Sik Oh, Seong-Hwan Son, Beong-Hee Yu, Kyeong-So Wee, Eun-Jong Lee, Young-Ki Lee, Jung-Woo Noh, Seung-Jung Kim, Kyu-Bok Choi, Suk-Hee Yu, Heui-Jung Pyo, Young-Joo Kwon
Korean J Intern Med. 2010;25(4):415-421. Published online November 27, 2010
Background/AimsFabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL..
|